Adamax
Next-Generation Semax Derivative · Nootropic Neuropeptide
Synthetic nootropic peptide with N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration, researched for cognitive enhancement, neuroprotection, and neuroplasticity.
Overview
Synthetic nootropic peptide with N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration, researched for cognitive enhancement, neuroprotection, and neuroplasticity.
Crosses BBB via enhanced lipophilicity from adamantane; upregulates BDNF and TrkB receptor sensitivity; modulates dopamine, norepinephrine, and serotonin; stabilizes microtubules via ADNP-derived mechanisms; provides antioxidant and anti-inflammatory neuroprotection.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Preliminary research suggests improvements in focus, mental clarity, memory consolidation, and complex task handling.
BDNF upregulation and TrkB enhancement promote new neural connections and synaptic plasticity for long-term improvements.
May enhance memory formation, information retention, and learning efficiency through hippocampal BDNF-TrkB pathway activation.
Preliminary observations indicate improved neurological outcomes through oxidative stress reduction and neuronal repair.
Demonstrates antioxidant properties protecting against oxidative damage and inflammation-induced neuronal injury.
Supports neuronal survival and growth through BDNF enhancement and microtubule stabilization.
Influences serotonin and dopamine to elevate mood and reduce depressive symptoms through neurotransmitter modulation.
Anecdotal reports indicate reduced overwhelm and anxiety through balanced neurotransmitter activity.
HPA axis modulation may improve stress response and emotional well-being.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Modified heptapeptide derivative
- Chain length
- 9 residues
- Molecular weight
- 1032.24 Da
- Half-life
- ~9 h
- Typical dose
- 200-300mcg
- Frequency
- Once daily, or twice for enhanced neuroprotection
- Cycle length
- 2-4 weeks
- Storage
- Lyophilized: room temp or freezer. Reconstituted: 2-8°C for 14-30 days
Molecular data
- Type
- Modified heptapeptide derivative
- Molecular weight
- 1032.24 Da
- Chain length
- 9 residues
- Half-life
- 540 min
Dosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Cognitive Enhancement | SubQ | 200-300mcg | 1x daily |
| Neuroprotection | SubQ | 300mcg | 1-2x daily |
| Mood Support | SubQ | 200mcg | 1x daily (morning) |
| Initial Trial | SubQ | 100-200mcg | 1x daily |
| Cognitive Enhancement | Oral/Sublingual | 100-200mg | 1x daily (morning) |
| Sustained Focus | Oral/Sublingual | 100-200mg | 2x daily (morning, early afternoon) |
| Mood Support | Oral/Sublingual | 100mg | 1x daily (morning) |
| Initial Assessment | Oral/Sublingual | 100mg | 1x daily |
Interactions
Adamax is an enhanced derivative with improved stability and bioavailability.
Adamax incorporates adamantyl portion from P21; may complement cognitive benefits.
Different mechanisms—Adamax targets neurological function; BPC-157 focuses on tissue repair.
Both enhance cognition through different mechanisms but share BDNF upregulation; start lower doses and monitor for overstimulation.
Quality checklist
- ✓White, fluffy powder indicating proper freeze-drying
- ✓Clear solution after reconstitution with no particles or cloudiness
- ✓Proper labeling with peptide name, batch number, manufacturing date
- !Slight compaction from shipping acceptable if powder dissolves completely
- ×Discoloration or yellowing indicates oxidation or degradation
- ×Persistent cloudiness or particles indicate degradation or contamination
What to expect
Safety
- Headaches (particularly at higher doses)
- Insomnia or sleep disruption
- Anxiety or overstimulation
- Cardiovascular effects (elevated blood pressure, palpitations)
- Persistent or severe headaches
- Chest pain, heart palpitations, or significant blood pressure increases
- Severe anxiety, insomnia, or mood disturbances
- Unusual neurological symptoms or mental status changes
- Persistent injection site reactions or infection signs
- Gastrointestinal distress (nausea, vomiting, diarrhea)
- Pregnancy and breastfeeding
- Cardiovascular conditions (without medical supervision)
- Severe anxiety disorders
- Uncontrolled hypertension
FAQ
How does Adamax improve cognition differently than Semax?
Adamax is a next-generation Semax derivative with C-terminal adamantane modification for enhanced lipophilicity and blood-brain barrier penetration. While parent Semax shows cognitive benefits, Adamax's superior stability and BBB crossing potentially enable stronger cognitive effects at lower doses and with more sustained action.
Can Adamax cause overstimulation if combined with other nootropics?
Yes. Adamax shares BDNF upregulation with compounds like Noopept, so combining them risks excessive neurotropic effects. Start with lower doses and monitor for overstimulation, anxiety, or sleep disruption. Safe stacking requires careful dose titration and might be better avoided for most users.
What causes the headaches some people report on Adamax?
Headaches are most common at higher doses (particularly above 300mcg). This likely relates to the potent dopamine, norepinephrine, and serotonin modulation combined with BDNF upregulation creating temporary neurochemical shifts. Starting at 100-200mcg and titrating slowly minimizes this risk.
How long do Adamax's cognitive effects last after stopping?
Due to BDNF-mediated neuroplasticity improvements, cognitive benefits persist weeks or months beyond discontinuation. Peak neuroprotective and structural brain benefits appear by week 4+ with continuous use, but the neuronal changes induced by BDNF upregulation have lasting effects independent of the compound remaining in circulation.
References
- 1A Nootropic Adrenocorticotropin Analog 4-10 Semax: 15 Years Experience in Its Design and Study (Parent Compound)Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al. · Zhurnal Vysshei Nervnoi Deiatelnosti imeni I.P. Pavlova · 1997
Foundational Semax review: intranasal doses stimulate operative memory and attention for 20-24 hours. Adamax builds on the Semax core sequence with adamantane modification for enhanced stability and BBB penetration.
reviewPubMed 9173745 ↗ - 2Semax, an Analog of ACTH(4-10), Regulates BDNF and trkB Expression in the Rat Hippocampus (Parent Compound)Dolotov OV, Karpenko EA, Inozemtseva LS, et al. · Brain Research · 2006
Single application at 50 mcg/kg produced 1.4-fold increase in BDNF protein and 1.6-fold increase in trkB tyrosine phosphorylation in rat hippocampus, supporting Adamax's BDNF-TrkB mechanism.
animalPubMed 16996037 ↗ - 3The Peptide Semax Affects the Expression of Genes Related to the Immune and Vascular Systems in Rat Brain Focal Ischemia (Parent Compound)Dergunova LV, Limborska SA, et al. · BMC Genomics · 2014
Genome-wide analysis: Semax modulated 24 vascular genes at 3h and enhanced immune-response gene expression at 24h post-ischemia, demonstrating multi-pathway neuroprotection.
animalPubMed 24661604 ↗ - 4The Efficacy of Semax in the Treatment of Patients at Different Stages of Ischemic Stroke (Parent Compound)Gusev EI, Barskov IV, et al. · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · 2018
110 ischemic stroke patients; Semax (6000 mcg/day intranasal) increased BDNF plasma levels and accelerated functional recovery, providing the clinical basis for Adamax neuroprotective applications.
reviewPubMed 29798983 ↗